Facts and figures
About the Ypsomed Group
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife™ Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1 350 employees.
Ypsomed Diabetes Care
With its mylife Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
After a successful 2016/17 we will grow by approximately 15 % in terms of turnover in the financial year 2017/18. In terms of EBIT, we are planning for the same or a slightly higher result as in the past year.
Key financial figures – four-year overview
|In thousand CHF||Year|
|Sales of goods and services||389 555||336 922||306 632||276 257|
|Gross profit||125 478||103 187||85 850||70 526|
|Operating profit||55 298||44 435||28 546||15 645|
|Net profit||46 247||35 812||19 395||13 608|
|EBITDA 1||87 763||73 270||57 369||40 715|
|Cash flow from operating activities||75 064||76 687||41 381||41 206|
|Headcount||1 314||1 166||1 050||999|
1 Operating proﬁt before depreciation and amortisation.